Faricimab Biosimilar – Anti-ANGPT2, VEGFA mAb – Research Grade

Description of Faricimab Biosimilar - Anti-ANGPT2, VEGFA mAb - Research Grade

About Faricimab biosimilar

Faricimab is a bispecific monoclonal antibody. This antibody is especially part of the human immunoglobulin G1-kappa-lambda type. It is targeting angiopoetin 2 (ANGPT2) and Vascular Endothelial Growth factor A (VEGFA). Both of these factors play key roles in angiogenesis and endothelial development respectively. Angiopoetin 2 is essential for normal vascular development as VEGF-A, which is an endothelial cell mitogen. Angiopoetin 2 is involved especially in vascular morphogenesis and homeostasis, and is mostly expressed in endothelial cells.
The expression of VEGF-A is shown to be up regulated in inflamed and vascularized human corneas. VEGF-A is therefore a target of choice to treat patients with retinal vascular diseases such as a retinal vein occlusion, Age related macular degeneration (AMD) and diabetic macular edema. Indeed, these diseases are caused by retinal ischemia and subsequent neovascularization.

A research grade biosimilar

Faricimab biosimilar is a humanized antibody based on on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.

Faricimab Biosimilar - Anti-ANGPT2, VEGFA mAb binds to Human ANGPT2 in indirect ELISA Assay

Immobilized Human ANGPT2-Ang2 recombinant protein (cat. No. PX-P6245) at 0.5µg/mL (100µL/well) can bind Faricimab Biosimilar - Anti-ANGPT2, VEGFA mAb (cat. No. PX-TA1501) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 66.43M.

Faricimab Biosimilar - Anti-ANGPT2, VEGFA mAb, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.